首页 正文

Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis

{{output}}
Over the past two decades, experimental and clinical evidence has established the interleukin-23 (IL-23)/interleukin-17 (IL-17) axis as a key mediator of psoriatic inflammation. IL-23, primarily derived from activated dendritic cells, supports the survival and... ...